{"id":"W1966629200","doi":"10.1016/j.eururo.2008.07.026","title":"Re: Bevacizumab plus Interferon alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial","year":2008,"lang":"en","type":"letter","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Renal cell carcinoma; Bevacizumab; Oncology; Internal medicine; Interferon alfa; Interferon; Urology; Chemotherapy; Immunotherapy; Cancer; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001657475,0.0009388031,0.00241023,0.0002743011,0.0004186644,0.0008550936,0.0007026862,0.00543158,0.006470328],"category_scores_gemma":[0.003859684,0.0003822994,0.001002355,0.0002418982,0.0005423503,0.0009436472,0.0002235811,0.004260328,0.001365421],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009296852,"about_ca_system_score_gemma":0.0008001163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009050485,"about_ca_topic_score_gemma":0.002763316,"domain_scores_codex":[0.9993621,0.0003847737,0.00004067442,0.00008333402,0.00005803228,0.00007122133],"domain_scores_gemma":[0.9989281,0.0006124424,0.0001670023,0.00003847157,0.00005455548,0.0001994674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.81875,0.001741943,0.001151351,0.002716208,0.00194747,0.0009159386,0.0001256577,0.0006812711,0.004062969,0.001116897,0.07162438,0.09516585],"study_design_scores_gemma":[0.9781851,0.008139582,0.001197732,0.0001777373,0.0005358117,0.0001903043,0.00002576352,0.0006300672,0.0004200173,0.000703348,0.009770968,0.00002355897],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.6197238,0.106736,0.004635093,0.186227,0.03586263,0.007055235,0.007114731,0.001200064,0.03144546],"genre_scores_gemma":[0.8351941,0.01500225,0.004695471,0.09367237,0.007367013,0.005849736,0.002060045,0.0001089908,0.0360499],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.006470328,"threshold_uncertainty_score":0.02164537,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09391503087787555,"score_gpt":0.3151565272663038,"score_spread":0.2212414963884283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}